VectorialDATA
Stocks/IEX

IEX — IDEX Corporation

IndustrialsNorth AmericaUnited StatesBlockchain certified

Price when we picked it (Jul 9, 2026)

$220.84

Target: $237.71 (+7.6%)

P/E Ratio

32.3

P/E Forward

25.2

Dividend

1.3%

Market Cap

$16.3B

EPS

$6.76

Consensus

Buy

What they do

IDEX Corporation (NYSE: IEX) is a niche industrial conglomerate. It doesn't make one famous product: it owns dozens of small companies that build critical — often invisible — parts for industry, medicine and safety. The idea is simple and powerful: buy the leader of a very specific corner of the market, improve it, and use the cash it generates to buy the next one. That's called an 'industrial compounder'.

The 3 businesses (segments):

  • Fluid & Metering Technologies (FMT) — precision fluid pumps, flow meters, valves and injectors. They move and measure liquids and chemicals with precision in water, energy, agriculture, chemicals and food. It's the most 'classic', industrial business.
  • Health & Science Technologies (HST) — the fastest-growing business. It makes precision fluidics and optics: the parts that move microscopic droplets of liquid inside medical diagnostic, lab analysis and scientific instrument machines. This is where the Mott Corporation acquisition landed (sintered porous metal filtration, ~$1 billion in 2024). In Q1 2026 this segment grew +17%.
  • Fire & Safety / Diversified Products (FSDP) — firefighting and rescue equipment: pumps for fire trucks and the hydraulic rescue tools (the 'jaws of life' that cut a car open to free an injured person), plus dispensing and clamping equipment.

Why the model works: each part IDEX makes is small within the total cost of its customer's machine, but critical — if the precision pump or the fluidics system fails, the whole machine is useless. That gives it pricing power, high margins and customers who don't switch suppliers lightly. With that cash, IDEX buys more businesses like these (disciplined 'bolt-on' M&A).

Leadership: CEO Eric Ashleman (in the role since December 2020, a company veteran). Headquartered in Northbrook, Illinois. ~9,000 employees worldwide.

Dividend (growing): ~$0.73 per share per quarter (raised in 2026; declared June 17, payable July 24) = ~$2.92 a year = ~1.3% at today's price. It has raised it 16 years in a row and paid it since 1995. Not a high dividend, but the kind that goes up like clockwork.

2026 context (what changed since our first purchase in April): a better-than-expected Q1 2026 — revenue $886.9 million (+9%, +5% organic), adjusted EPS $2.00 (+14%), record orders of $988.3 million (+13%) and adjusted EBITDA of $230.4 million (26.0% margin). The company raised its full-year organic growth target from 1-2% to 3-4% and its adjusted EPS guidance to $8.35-$8.55 per share.

Why we like it

IEX at $220.84 is reinforcing a position we already held since April (~$197.85): it's not a new idea, it's doubling down on a quality business whose thesis got stronger. Specific reasons:

  • The thesis was confirmed, that's why we're reinforcing: when we bought in April, we were betting on a high-margin industrial compounder in the middle of a cyclical recovery. Since then it reported a better-than-expected Q1 2026 (adjusted EPS $2.00 vs ~$1.78 expected), record orders of $988.3 million (+13%) and raised its full-year growth target from 1-2% to 3-4%. The recovery is real, not a hope — which is why we paid ~12% more than in April without hesitation.
  • The compounder model: IDEX doesn't depend on a trendy product; it owns dozens of small niche leaders, generates lots of cash and reinvests it buying more (Mott, ~$1 billion, is the big recent example). It's a disciplined, decades-proven acquisition machine.
  • Small but critical parts = high margins: each IDEX component is cheap within the customer's machine but indispensable; that gives it pricing power and a ~26% EBITDA margin few industrials reach.
  • The dividend that rises like clockwork: 16 straight years of increases, paid since 1995 — the sign of a company that generates cash to spare and treats shareholders well, even if the yield (~1.3%) is modest.
  • Wall Street backs it: 'Buy' consensus (57% say 'Strong Buy'), average target of ~$238 across 15 analysts. Honesty: the average upside is moderate (~+8%) and the stock isn't cheap (~32x trailing earnings) — here you're not buying a discount, you're buying quality that compounds over time.

Key Risk

Risks:

  • Premium valuation — the #1: IDEX is rarely cheap and it isn't today: ~32x trailing earnings and ~25x forward, with an average target (~$238) barely ~8% above today's price. It's an excellent business at a fair price, not a bargain — at these multiples, a stumble gets punished fast.
  • Industrial cyclicality: much of its sales depend on factories, power plants, agriculture and industrial customers continuing to invest; when the economy slows, those orders get postponed and IDEX's sales fall (it lived this in 2023-2024, when growth flattened before this recovery).
  • Acquisition integration risk: the whole model depends on buying well and digesting well; if it overpays for a business (Mott came at ~19x EBITDA) or the integration fails, the 'compounding' breaks and growth stalls.
  • Exposure to many different end markets: IDEX touches dozens of industries (water, health, semiconductors, firefighting, energy); that diversification protects, but it also means there's always some weak segment dragging on the rest — full-year organic growth is only 3-4%.
  • Dependence on cash to grow: if cash goes to acquisition debt or rates rise, there's less fuel for the M&A engine that sustains the thesis.
  • It's not an income dividend: anyone looking for high income won't find it here (~1.3%); if growth disappoints, there's no generous yield to compensate the wait.

This is educational and informational content, not financial advice. Always consult a qualified financial advisor before making investment decisions.

Vectorial Data picked IEX on Apr 8, 2026 at $197.85.

Full Research

IDEX Corporation (IEX) — Full Research (RE-BUY)

Price: $220.84 | P/E TTM: ~32.3x | P/E fwd: ~25.2x | Div Yield: ~1.3% | Market Cap: ~$16.3 billion USD

Re-buy: IDEX was already in the portfolio since April 2026 (~$197.85). Today we reinforce it at $220.84 (~+12%) because the thesis was confirmed by Q1 2026 and the raised guidance.

What is IDEX?

A niche industrial conglomerate ('industrial compounder'): instead of a star product, it owns dozens of small companies that lead very specific corners of industry. It buys the leader of a niche, improves it, and reinvests the cash it generates buying the next one. Headquartered in Northbrook, Illinois. ~9,000 employees. CEO: Eric Ashleman (since December 2020).

The 3 businesses (segments)

SegmentWhat it is
Fluid & Metering Technologies (FMT)Precision pumps, flow meters, valves and injectors for water, energy, agriculture, chemicals and food
Health & Science Technologies (HST)Precision fluidics and optics for medical diagnostics, lab analysis and scientific instruments (includes Mott). In Q1 2026 it grew +17%
Fire & Safety / Diversified Products (FSDP)Pumps for fire trucks, hydraulic rescue tools ('jaws of life'), dispensing and clamping

Latest quarter (Q1 2026)

MetricQ1 2026
Net sales$886.9 million (+9% total, +5% organic)
OrdersRecord: $988.3 million (+13% reported, +10% organic)
GAAP net income$120.0 million
GAAP diluted EPS$1.61 (from $1.26 a year earlier)
Adjusted EPS$2.00 (+14%) — above the ~$1.78 expected
Adjusted EBITDA$230.4 million (26.0% margin)
Standout segmentHealth & Science Technologies +17%

FY2026 guidance (raised after Q1)

MetricGuidance
Organic growth3%-4% (raised from 1%-2%)
Adjusted EPS$8.35-$8.55
Adjusted EBITDA margin26.5%-27.0%

What changed since our first purchase (April 2026, ~$197.85)

  • Q1 2026 beat expectations (adjusted EPS $2.00 vs ~$1.78 expected).
  • Record orders of $988.3 million (+13%) — the best sign the cyclical recovery is real.
  • Raised the full-year organic growth guide from 1-2% to 3-4%.
  • Raised the dividend to ~$0.73/quarter (declared Jun 17, 2026).
  • The price rose ~12% (from ~$197.85 to $220.84), but the compounder thesis is intact and better supported.

The compounder model

  • Small but critical parts: each IDEX component is cheap within the customer's machine but indispensable — pricing power + loyal customers + ~26% EBITDA margin.
  • Disciplined 'bolt-on' M&A: reinvests cash buying more niche leaders. The biggest recent one: Mott Corporation (sintered porous metal filtration, ~$1 billion, closed September 2024, within HST).
  • Diversification: touches dozens of end markets (water, health, science, energy, firefighting), which softens the blow of any single industry.

Dividend (growing, not income)

  • ~$0.73 per share per quarter (raised in 2026; declared Jun 17, 2026, payable Jul 24, 2026) → ~$2.92 a year = ~1.3% at $220.84.
  • 16 consecutive years of increases; paid since 1995. Modest yield, but a machine for raising it every year.

Leadership

  • CEO: Eric Ashleman (since December 2020; a company veteran who previously ran the FSDP and HST segments).
  • Headquarters: Northbrook, Illinois. ~9,000 employees; ~74.0 million shares outstanding.

Anchor Fact

IDEX doesn't make one famous product: it owns dozens of small companies that lead very specific niches — a precision pump here, the part that moves the liquid inside a medical analysis machine there, the tools firefighters use to rescue people. Each one is tiny, but together they form a machine that grows by buying more pieces of the puzzle and raises its dividend 16 years in a row.

Top 6 Risks

  • Premium valuation — ~32x TTM earnings, ~25x forward; average target (~$238) only ~8% above; not a bargain
  • Industrial cyclicality — depends on factories and industrial customers continuing to invest; flattened in 2023-2024 before this recovery
  • M&A integration — the model depends on buying and digesting well; overpaying (Mott at ~19x EBITDA) or a failed integration breaks the compounding
  • Many end markets — diversification protects but there's always a weak segment; organic growth of only 3-4%
  • Cash dependence — less fuel for the acquisition engine if debt or rates rise
  • Not an income dividend — ~1.3% doesn't compensate if growth disappoints

Analyst Consensus

  • Rating: Buy (~57% 'Strong Buy', ~29% 'Buy', ~14% 'Hold', 0% 'Sell')
  • Average target: ~$237.71 (~+8% from $220.84); range $210-$260; 15 analysts
  • Honest read: moderate average upside and a demanding valuation. Here you're not buying a discount — you're buying a quality compounder, and we reinforced because the thesis was confirmed.

One-line thesis

A quiet buy-and-improve machine of small niche leaders: invisible but critical parts, high margins, a dividend that rises 16 years in a row — and a record Q1 2026 that confirmed the recovery and made us reinforce the position.

Research date: Jul 9, 2026 | Next review: Jan 2027

This is not financial advice.

More picks in Industrials

See all Industrials picks →

More picks from United States

See all picks from United States →
Researched: Apr 8, 2026Updated: Jul 9, 2026Next review: Jan 9, 2027

This is not financial advice. Consult a certified financial advisor.

The author may hold positions in the securities discussed.

Past performance does not guarantee future results.